(HealthDay News) — A prostate-specific antigen cut point of ≥0.4 ng/mL predicts future disease progression, according to a study published in The Journal of Urology.
Amir Toussi, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues reviewed long-term prostatectomy outcomes to examine the most appropriate prostate-specific antigen cut point that predicts subsequent disease progression. Data were included for 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy.
The researchers found that a detectable prostate-specific antigen developed in 5,041 patients at a median postoperative follow-up of 9.1 years, and systemic progression developed in 512 patients. The percentage of patients experiencing a continued prostate-specific antigen increase over 5 years was 61, 67, and 74%, respectively, after reaching the prostate-specific antigen cut point of 0.2, 0.3, and 0.4 ng/mL, plateauing at 0.4 ng/mL. The strongest correlation between biochemical recurrence and systemic progression was seen for a single prostate-specific antigen cut point of 0.4 ng/mL or more.
“A prostate-specific antigen cut point of 0.4 ng/mL or greater reflects the threshold at which a prostate-specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression,” the authors write.
- Toussi A, Stewart-Merrill SB, Boorjian SA, et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy—What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol; doi: 10.1016/j.juro.2015.12.075.
- Tosoian JJ and Pierorazio PM. Optimizing Use of Serum Prostate Specific Antigen to Define Biochemical Recurrence—Is There a Method to the Madness? J Urol; doi: 10.1016/j.juro.2016.03.068.